The use of cetuximab in the continuum of care for patients with metastatic colorectal cancer
The anti-epidermal growth factor receptor (EGFR) monoclonal antibody cetuximab in combination with chemotherapy is the standard of care in the first-line treatment for RAS wild-type metastatic colorectal cancer (mCRC), and it may also be effective in further lines of therapy. After the first-line ce...
Wedi'i Gadw mewn:
| Prif Awduron: | , |
|---|---|
| Fformat: | Artigo |
| Iaith: | Inglês |
| Cyhoeddwyd: |
Editorial Office of China Oncology
2020-01-01
|
| Cyfres: | Zhongguo aizheng zazhi |
| Pynciau: | |
| Mynediad Ar-lein: | http://www.china-oncology.com/thesisDetails#10.19401/j.cnki.1007-3639.2020.01.008 |
| Tagiau: |
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!
|